Study questions rate of antibiotic treatment in hospice | CMS raising standards for reporting by hospices | Methylprednisolone doesn't boost opioid's effect against cancer pain
Web Version
 
 
July 16, 2014
Hospice and Palliative Medicine SmartBrief
News for physicians caring for the seriously ill
SIGN UP|FORWARD|ARCHIVE|ADVERTISE

Top StorySponsored By
Study questions rate of antibiotic treatment in hospice
Antibiotic use is common for hospice patients despite a lack of evidence for its benefits, according to a study in the journal Antimicrobial Agents and Chemotherapy. Researchers in Oregon found that about 1 in 5 patients discharged to hospice are given antibiotics, but antibiotics may not work near the end of life, lead investigator Jon Furuno said. McKnight's Long-Term Care News (7/15)
Share: LinkedInTwitterFacebookGoogle+Email
Take Action to Make the World a Better Place
Earn your Master's of Social Work with a clinical focus online at The Catholic University of America. Choose your own field placement. This values-based degree uses a comprehensive, demanding curriculum to ready you for real-world application and prepare for your license in clinical social work.
 
Palliative & Hospice Care Update
CMS raising standards for reporting by hospices
The CMS is taking a greater interest in tracking data on hospices as the field has grown. Final rules on reporting are being developed, but the agency has estimated that gathering and submitting data could take 180 hours. Healthcare Finance News (7/11)
Share: LinkedInTwitterFacebookGoogle+Email
Methylprednisolone doesn't boost opioid's effect against cancer pain
Methylprednisolone does not appear to improve the pain-relieving benefits of opioid therapy for cancer pain, according to a randomized 50-patient study reported in the Journal of Clinical Oncology. No significant differences were seen after seven days in medicine use or pain relief. Patients who received methylprednisolone did report less fatigue and better appetites. PhysiciansBriefing.com/HealthDay News (7/15)
Share: LinkedInTwitterFacebookGoogle+Email
Patient & Family Perspective
Chaplain: "You don't listen only to people's words"
Visiting Nurse Service of New York spiritual care counselor Kei Okada helps people who are searching for meaning near the end of life. Okada recalls being accosted by the husband of a patient early in his career. "He saw my student chaplain badge and started yelling at me that there was no God. That was a breakthrough moment for me. I realized that at a time like this, you don't listen only to people's words; you listen to their heart," Okada said. The New York Times (tiered subscription model) (7/12)
Share: LinkedInTwitterFacebookGoogle+Email
 
Medical Research
Dementia diagnosis rate on the decline, research indicates
The rate of diagnosis for dementia appears to be declining over the short and long term, according to three studies being presented at the Alzheimer's Association International Conference. One study found the diagnosis rate is down 44% from the late 1970s in the U.S., and a second study showed a similar decline based on data from the U.S., England, Sweden and the Netherlands. The greatest gains were seen among people in their 60s. The third study found the risk of dementia declined in Germany from 2004 to 2007. HealthDay News (7/15)
Share: LinkedInTwitterFacebookGoogle+Email
Diabetes drug might lower dementia risk
Seniors taking the inexpensive diabetes drug pioglitazone had significantly reduced odds of dementia onset with every additional three months the drug was prescribed, German researchers found. The researchers analyzed data involving about 146,000 patients age 60 and older who had not been diagnosed with dementia. The results of the analysis were presented at the Alzheimer's Association International Conference. Reuters (7/14)
Share: LinkedInTwitterFacebookGoogle+Email
Health Policy & Practice
Alzheimer's disease researchers focus on prevention, delaying onset
Research that found diet, exercise and other behavioral changes could delay the onset of Alzheimer's disease symptoms is among a growing number of studies focusing on delaying or preventing symptoms of Alzheimer's and dementia. The largest trials involve thousands of participants and are funded by foundations, governments and drugmakers. "Forestalling the appearance of symptoms by five to 10 years would have a tremendous public health impact," Laurie Ryan of the National Institute on Aging said. The Wall Street Journal (tiered subscription model) (7/15)
Share: LinkedInTwitterFacebookGoogle+Email
N.Y. bill would highlight availability of LTCI
New York lawmakers have approved a bill that would allow life insurers to use end-of-life care, such as hospice care, as a trigger for access to accelerated death benefits. Another provision in the bill would allow the state health department to work with both the state office on aging and the tax office on a campaign to raise public awareness of long-term care insurance plans. National Underwriter Life & Health (7/14)
Share: LinkedInTwitterFacebookGoogle+Email
FDA could soon approve Salix's chronic pain drug
Salix Pharmaceuticals announced that the FDA has shown intent to approve an injectable formulation of its drug Relistor for the treatment of chronic pain in patients without cancer. The agency asked Salix to submit additional data from post-marketing observational studies, and Salix plans to submit the information within the next few weeks. The News & Observer (Raleigh, N.C.)/.Biz blog (7/14)
Share: LinkedInTwitterFacebookGoogle+Email
Trends & Technology
Startup offers tech to help apps follow data-privacy laws
Medable provides an application programming interface and a software development kit in its service platform to help application developers comply with federal health-privacy regulations. "Mobile apps can make it easy for users to communicate with their doctors, nurses and caregivers," Medable co-founder Michelle Longmire notes. VentureBeat (7/14)
Share: LinkedInTwitterFacebookGoogle+Email
Support Hospice and Palliative Medicine SmartBrief
Hospice and Palliative Medicine SmartBrief is the twice-weekly e-news resource for 8,000 influential leaders in hospice and palliative care. E-mail Wynn Hansen for more information on advertising.
 
AAHPM News
Submit a scientific proposal for the 2015 AAHPM & HPNA Annual Assembly
Are you interested in presenting at the 2015 Annual Assembly in Philadelphia? AAHPM and HPNA's call for scientific papers and posters is open through Aug. 1. Submit today!
Share: LinkedInTwitterFacebookGoogle+Email
AAHPM Intensive Board Review Course
Designed to help you prepare for the board examination in hospice and palliative medicine and to advance the clinical competence of all practitioners in the field, including physician assistants and nurse practitioners. This course features face-paced didactic sessions with panel discussions. Topics include pain assessment and management, pediatric pain management and care, nonpain symptoms, urgent medical conditions, and much more. Register now!
Share: LinkedInTwitterFacebookGoogle+Email
Who's Hiring?
Position TitleCompany NameLocation
Hospice and Palliative Physician, Associate Medical DirectorHospice of YumaYuma, AZ
Palliative Medicine Physician - Suburban AtlantaWellStar Health SystemDouglasville, GA
Ideal Palliative Care Physician Opportunity - Beautiful Greenville, SCGreenville Health SystemGreenville, SC
UCSF FRESNO PALLIATIVE MEDICINE FACULTY POSITIONUCSF FresnoFresno, CA
Click here to view more job listings.
 
SmartQuote
If I won't be myself, who will?"
-- Alfred Hitchcock,
British-American film director
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AAHPM ->About | Advocate | Join | Practice | Train | Certify | Learn | Shop
This newsletter is brought to you by the American Academy of Hospice and Palliative Medicine and SmartBrief.
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Tom Parks
Advertising:  Wynn Hansen
  P: 202.470.1149
 
 

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information